Navigation Links
Watson Confirms Favorable District Court Ruling in Generic Sanctura XR® Patent Suit
Date:4/3/2012

PARSIPPANY, N.J., April 3, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States District Court for the District of Delaware has ruled that the asserted claims of United States Patent Nos. 7,410,978 (the '978 Patent), 7,759,359 (the '359 Patent), 7,781,448 (the '448 Patent), 7,781,449 (the '449 Patent) and 7,763,635 (the '635 Patent) for Sanctura XR® (trospium chloride extended-release capsules) are invalid.  Watson's Abbreviated New Drug Application for a generic version of Sanctura XR® is pending with the Food and Drug Administration. 

Sanctura XR® is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. For the twelve months ending February 29, 2012, Sanctura XR® had total U.S. sales of approximately $68 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Sanctura XR® is a registered trademark of Allergan, Inc.

(Logo:  http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

 

 CONTACTS:Investors:Patty Eisenhaur (862) 261-8141Media:Charlie Mayr(862) 261-8030 


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2020)... ... 26, 2020 , ... Rize Health, an innovative ... provide them with revolutionary clinical trial solutions. , Through this strategic partnership, Rize ... that enables onboarding, scheduling, and remote data capture - right from your fingertips. ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... in mid-March 2020 to deliver thousands of critical Personal Protection Equipment (PPE) devices ... their usual aerospace production work, the three companies teamed together to start production ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... technologies and products in the global health and medical technology market, today announced ... has been selected as the winner of its “Health Administration Innovation Award” in ...
Breaking Medicine Technology:
(Date:5/27/2020)... ... 27, 2020 , ... Radiology Associates of Richmond (RAR), one ... aligned with the Strategic Radiology (SR) coalition of independent practices. , RAR ... coalition, which has 28 member practices in 20 different states. The Richmond practice ...
(Date:5/26/2020)... ... ... Sex educator, activist, humanitarian, and Wicked Pictures star jessica drake and ... Audio Visual Award for jessica drake's Guide to Wicked Sex: Senior Sex. The collaborative ... in its demonstrations and narratives and was produced and distributed by Wicked Pictures. ...
(Date:5/21/2020)... ... May 21, 2020 , ... Summit Medical ... to deliver over one million FDA-compliant face shields — designed, engineered and manufactured ... the critical need for personal protective equipment (PPE) for both front-line health care ...
(Date:5/21/2020)... , ... May 21, 2020 , ... ... at Home Order” will be lifted on May 28th and all businesses will ... for local companies returning back to work. , As an essential business, AmeriCare ...
(Date:5/21/2020)... ... ... JNL Technologies Inc. , a manufacturer of safety and security products ... screening software. This tool allows companies to create an electronic screening record of anyone ... paperwork management. , SafeHealth allows you to create a custom set of screening questions, ...
Breaking Medicine News(10 mins):